<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141238">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01913483</url>
  </required_header>
  <id_info>
    <org_study_id>MDCO-BIV-12-03</org_study_id>
    <nct_id>NCT01913483</nct_id>
  </id_info>
  <brief_title>ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial</brief_title>
  <acronym>ENDOMAX</acronym>
  <official_title>ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to demonstrate that anticoagulation with bivalirudin
      results in fewer major bleeding complications compared with unfractionated heparin (UFH) in
      subjects undergoing peripheral endovascular interventions (PEI). The secondary objective is
      to identify potential benefits from bivalirudin therapy on other clinically important events
      such as death, myocardial infarction (MI), stroke and/or transient ischemic attack (TIA),
      amputation, unplanned repeat revascularization (URV), and minor bleeding, as well as
      potential economic benefits that may result from improved clinical outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Bleeding</measure>
    <time_frame>48 hrs</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bleeding defined as Bleeding Academic Research Consortium (BARC) ≥3 within 48 hours post study drug initiation or at hospital discharge, whichever occurs first, as adjudicated by the CEC</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3900</enrollment>
  <condition>Peripheral Endovascular Interventions</condition>
  <arm_group>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bivalirudin will be administered as a bolus and infusion. The bolus (0.75 mg/kg) will be administered via systemic IV administration.  Immediately after the bolus, an IV infusion of bivalirudin will be initiated at a dose of 1.75 mg/kg/h (or 1 mg/kg/h for subjects with an eGFR &lt;30 mL/min).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>UFH will be administered as an initial weight-based IV bolus at a dose of 50 units (U)/kg to 70 U/kg.  Additional bolus doses may be administered per the pre-defined heparin dosing algorithm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_label>Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects ≥ 18 years of age

          -  Must be undergoing one of the following PEI procedures:

               -  Carotid artery stenting (approximately 33% of study sample)

               -  Lower Extremity Interventions (LEI) for Critical Limb Ischemia (CLI)
                  (approximately 33% of study sample)

               -  LEI for claudication (approximately 33% of study sample)

          -  Provide written informed consent prior to any study-specific procedure being
             performed

        Exclusion Criteria:

          -  Any known contra-indication to the use of bivalirudin or UFH

          -  Acute limb ischemia

          -  Planned amputation regardless of the outcome of the PEI

          -  Dialysis dependent

          -  Weight less than 38 kilograms (kg) or more than 202 kg

          -  History of any bleeding diathesis or severe hematological disease

          -  History of intra-cranial: mass, aneurysm, arteriovenous malformation or hemorrhage

          -  Gastrointestinal or genitourinary bleeding within the 30 days prior to randomization

          -  Any surgery (including biopsy) within the 30 days prior to randomization

          -  Concomitant percutaneous coronary intervention (PCI)

          -  Any percutaneous coronary, endovascular, or structural heart disease procedure within
             30 days prior to randomization

          -  International normalized ratio (INR) &gt;1.7 within 24 hours (h) prior to the index
             procedure

          -  Administration of therapeutic doses of UFH within 30 min prior to the index procedure
             (a low dose [≤2000 units (U)] of  heparin is permitted during the diagnostic
             angiogram prior to the intervention)

          -  Administration of enoxaparin within 8 hours; other low molecular weight heparins
             (LMWHs) or fondaparinux within 24 hours; any oral anti-Xa or antithrombin agent
             within 48 hours; or thrombolytics, glycoprotein inhibitors (GPI) or warfarin within
             72 hours prior to the index procedure

          -  Severe contrast allergy that cannot be pre-medicated

          -  Procedures performed by radial access

          -  Known or suspected pregnant women or nursing mothers

          -  Previous enrollment in this study (MDCO-BIV-12-03)

          -  Participation in other investigational drug or device trials within 30 days prior to
             randomization, with the exception of ongoing participation in the EUCLID Trial which
             is permitted

          -  Subjects who, for any reason, are deemed by the investigator to be inappropriate for
             this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tara G Richardson</last_name>
    <phone>9732906103</phone>
    <email>tara.richardson@themedco.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenna Bisch</last_name>
    <phone>9732906171</phone>
    <email>jenna.bisch@themedco.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tri-Lakes Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyndi Tauth</last_name>
      <phone>501-625-3400</phone>
      <email>CTheart0469@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clearwater Cardiovascular and Interventional Consultants</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Cameron</last_name>
      <phone>727-449-9257</phone>
      <email>CameronM@cccheart.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Research Network</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt Malphurs, Pharmacist</last_name>
      <phone>352-333-0939</phone>
      <email>kurtm@flrnetwork.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwest Cardiovascular Research Foundation</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Park</last_name>
      <phone>563-324-4384</phone>
      <email>parkh@mcrfmd.com</email>
    </contact>
    <contact_backup>
      <last_name>Gail Shammas</last_name>
      <phone>563-324-4384</phone>
      <email>shammasg@mcrfmd.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Novant Health Heart and Vascular Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lance E. Diehl, MD</last_name>
      <phone>704-264-1400</phone>
      <email>lediehl@novanthealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LeBauer Cardiovascular Research Foundation</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Arida, MD</last_name>
      <phone>336-832-3799</phone>
      <email>muhammad.arida@conehealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AnMed Health</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Betsill, MS, RN, CNS</last_name>
      <phone>864-512-8734</phone>
      <email>kathy.betsill@anmedhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>March 14, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
